Clicky

Diamyd Medical AB (publ)(DMYD-B)

Description: Diamyd Medical AB (publ) develops therapies for the treatment of autoimmune diabetes. The company develops Diamyd, an antigen-specific immunotherapy diabetes vaccine, which is in phase III clinical trial for the treatment of type 1 diabetes and latent autoimmune diabetes; and Remygen, an oral regenerative and immunomodulatory drug candidate, which is in phase I/II clinical trial for the treatment of autoimmune and type 2 diabetes. The company was formerly known as Diamyd Therapeutics AB and changed its name to Diamyd Medical AB (publ) in April 2013. Diamyd Medical AB (publ) was incorporated in 1984 and is based in Stockholm, Sweden.


Keywords: Medicine Clinical Medicine Diabetes Organ Systems Immunotherapy Autoimmune Disease Autoimmunity Type 1 Diabetes

Home Page: www.diamyd.com

Kungsgatan 29
Stockholm, 111 56
Sweden
Phone: 46 86 61 00 26


Officers

Name Title
Mr. Ulf Hannelius MBA, Ph.D. CEO & Pres
Ms. Anna Styrud BSc Chief Financial Officer
Ms. Martina Widman Chief Operating Officer
Mr. Anton Lindqvist Chief Scientific Officer
Eva Karlstrom Chief Regulatory Affairs Officer
Christoph Nowak Chief Medical Officer

Exchange: ST

Country: SE : Sweden

Currency: Swedish krone (kr)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 5.6696
Price-to-Sales TTM: 2531.3528
IPO Date:
Fiscal Year End: August
Full Time Employees: 21
Back to stocks